Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Revenue (2018 - 2025)

Arcturus Therapeutics Holdings (ARCT) has disclosed Revenue for 8 consecutive years, with $7.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Revenue fell 68.39% year-over-year to $7.2 million, compared with a TTM value of $82.0 million through Dec 2025, down 46.14%, and an annual FY2025 reading of $82.0 million, down 46.14% over the prior year.
  • Revenue was $7.2 million for Q4 2025 at Arcturus Therapeutics Holdings, down from $17.2 million in the prior quarter.
  • Across five years, Revenue topped out at $160.3 million in Q4 2022 and bottomed at $2.0 million in Q2 2021.
  • Average Revenue over 5 years is $31.0 million, with a median of $24.9 million recorded in 2022.
  • The sharpest move saw Revenue skyrocketed 2666.53% in 2022, then crashed 80.75% in 2023.
  • Year by year, Revenue stood at $5.8 million in 2021, then surged by 2666.53% to $160.3 million in 2022, then plummeted by 80.75% to $30.9 million in 2023, then fell by 26.22% to $22.8 million in 2024, then tumbled by 68.39% to $7.2 million in 2025.
  • Business Quant data shows Revenue for ARCT at $7.2 million in Q4 2025, $17.2 million in Q3 2025, and $28.3 million in Q2 2025.